ImmunityBio (IBRX) Free Cash Flow (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Free Cash Flow of -$76.5 million for Q1 2026, up 11.0% year-over-year from -$68.9 million in Q1 2025, and down 7.48% quarter-over-quarter from -$71.1 million in Q4 2025.
Powered by 
Analysis
ImmunityBio (IBRX) Free Cash Flow (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Free Cash Flow for 13 consecutive years, with -$76.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 11.0% year-over-year to -$76.5 million; the TTM figure through Mar 2026 stood at -$296.8 million (up 19.78% YoY), while the FY2025 annual figure was -$306.3 million, up 21.94% from the prior year.
- Free Cash Flow declined to -$76.5 million in Q1 2026 per IBRX's latest filing, from -$71.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$67.2 million in Q3 2025 and bottomed at -$134.6 million in Q2 2022.
- Historically, Free Cash Flow has averaged -$91.5 million across 5 years, with a median of -$85.9 million in 2025.
- Annual changes were most pronounced in 2022 — Free Cash Flow sank 93.66% — and 2023, when it soared 42.3%.
- ImmunityBio's Free Cash Flow stood at -$109.7 million in 2022, then rose by 6.43% to -$102.6 million in 2023, then grew by 20.59% to -$81.5 million in 2024, then rose by 12.69% to -$71.1 million in 2025, then decreased by 7.48% to -$76.5 million in 2026.
- Business Quant data shows IBRX's Free Cash Flow at -$76.5 million in Q1 2026, -$71.1 million in Q4 2025, and -$67.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 10 | ImmunityBio | 8.45 Bn | 8.10 Bn | 50.94 Mn | -70.02 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -70.02 Mn |
| Mar 31, 2026 | -77.18 Mn |
| Dec 31, 2025 | -71.24 Mn |
| Sep 30, 2025 | -69.69 Mn |
| Jun 30, 2025 | -80.83 Mn |
| Mar 31, 2025 | -87.03 Mn |
| Dec 31, 2024 | -87.26 Mn |
| Sep 30, 2024 | -100.55 Mn |
| Jun 30, 2024 | -101.96 Mn |
| Mar 31, 2024 | -108.36 Mn |
| Dec 31, 2023 | -123.23 Mn |
| Sep 30, 2023 | -93.08 Mn |
| Jun 30, 2023 | -77.69 Mn |
| Mar 31, 2023 | -103.34 Mn |
| Dec 31, 2022 | -109.66 Mn |
| Sep 30, 2022 | -96.54 Mn |
| Jun 30, 2022 | -107.20 Mn |
| Mar 31, 2022 | -102.28 Mn |
| Dec 31, 2021 | -82.04 Mn |
| Sep 30, 2021 | -80.75 Mn |